

BBCIC Planning Board Members:

- Planning Board Chairperson: Mark Cziraky, PharmD, Co-Founder and VP of Research, Anthem/Healthcore
- Jerry Clewell, PharmD, MBA, Associate Scientific Director, Biotherapeutics Strategy, AbbVie
- Elizabeth Engelhardt, RN MSCN, VP, Specialty Product, Aetna
- Thomas Felix, MD, Director, R&D Policy, Global Regulatory Affairs , Amgen, Inc.
- Dottie McCabe, PhD, FCP, Executive Director, Clinical Development & Medical Affairs, General Medicine, Immunology & CNS, Boehringer-Ingelheim
- James R. Van Lieshout, Vice President, Market Access and Pharmacy Strategy, Apobiologix
- Amy Gross, PharmD, BCPP, Director, Clinical Specialists, Express Scripts Inc
- Karen Birmingham, PharmD, Manager, Pharmacy Infusion Program and Medication Safety, Group Health Research Institute
- Jeffrey S. Brown, PhD, Associate Director, FDA Mini-Sentinel & Associate Professor, Department of Population Medicine, Harvard Pilgrim Health Care Institute
- James Kenney, MBA, Manager, Specialty and Pharmacy Contracts, Harvard Pilgrim Health Plan
- Richard Bruzek, PharmD, VP Pharmacy Services, HealthPartners Institute for Education and Research
- Vanita K. Pindolia, PharmD, VP, Ambulatory Clinical Pharmacy Programs, Henry Ford Health System
- Phil Johnson, MS, RPh, FHOPA, FASHP, Chair, Hematology Oncology Pharmacy Association Health Policy Workgroup on Biosimilars
- Larry Radican, MPH, PhD, Executive Director, Global Outcomes Research, Merck
- Jan Hillson, MD, Senior Director, Clinical and Translational Research, Momenta
- Kelly Pokuta, PharmD, Senior Director, Specialty Pharmacy and Industry Relations, Optum
- Luiz Arantes, MD, MBA, Senior Director - Global Biosimilars Supportive Care Medical Lead, Pfizer Inc.
- Hillel Cohen, Hillel Cohen, MD, PhD, Executive Director, Scientific Affairs, Sandoz
- Planning Board Public Representative: Jeffrey R. Curtis, MD, MS, MPH, Co-Director, UAB Center for Education and Research on Therapeutics (CERTS), University of Alabama at Birmingham
- Planning Board Public Representative: Robert S. Miller MD, FACP, FASCO, Vice President, Quality and Guidelines, American Society of Clinical Oncology (ASCO)
- Planning Board Public Representative: Eleanor Perfetto, PhD, MS, Senior Vice President, Strategic Initiatives, National Health Council
- FDA Liaison: Robert Ball, MD, MPH, Deputy Director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- BBCIC Staff: Bernadette Eichelberger, PharmD, Program Director, BBCIC
- BBCIC Counsel: George Constantine, JD, Counsel, BBCIC